De novo amyloidosis in a renal allograft: a case report and review of the literature.
Recurrent amyloidosis is an uncommon but well-documented event in up to 26% of renal allograft recipients transplanted for amyloid renal disease. Both primary and secondary amyloidoses recur. De novo primary and secondary amyloid have not been previously reported. We report the first occurrence of de novo secondary amyloid in a renal allograft recipient. The cause of the secondary amyloidosis is unproven, but possible etiologies include inflammation secondary to occult hepatitis, rheumatoid arthritis, or chronic rejection. Colchicine therapy has not resulted in decreased proteinuria or improved renal function.
Harrison
K L
KL
Department of Medicine, University of Washington School of Medicine, Seattle.
Alpers
C E
CE
Davis
C L
CL
D000682:Amyloid / Q000032:analysis; D000686:Amyloidosis / Q000209:etiology* / Q000473:pathology; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology* / Q000473:pathology; D007678:Kidney Glomerulus / Q000473:pathology; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012008:Recurrence
D000682:Amyloid